Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

ARID1A promotes genomic stability through protecting telomere cohesion.

Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, Zundell J, Fukumoto T, Liu Q, Kossenkov A, Jean S, Cadungog MG, Borowsky ME, Drapkin R, Lieberman PM, Abate-Shen CT, Zhang R.

Nat Commun. 2019 Sep 6;10(1):4067. doi: 10.1038/s41467-019-12037-4.

2.

CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer.

Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW.

Sci Rep. 2018 Oct 3;8(1):14725. doi: 10.1038/s41598-018-32885-2.

3.

Malignant Transformation of Endometriosis in the Ischioanal Fossa.

Klebanoff JS, Shah SK, Cadungog MG.

Case Rep Obstet Gynecol. 2018 Apr 23;2018:5643040. doi: 10.1155/2018/5643040. eCollection 2018.

4.

Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.

Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, Nguyen JM, Curiel TJ, Cadungog MG, Singhal S, Eruslanov EB, Zhang P, Tchou J, Zhang R, Conejo-Garcia JR.

Cancer Discov. 2017 Jan;7(1):72-85. doi: 10.1158/2159-8290.CD-16-0502. Epub 2016 Sep 30.

5.

Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK, Wickramasinghe J, Nguyen JM, O'Brien SW, Gumireddy K, Huang Q, Cadungog MG, Connolly DC, Tchou J, Curiel TJ, Conejo-Garcia JR.

Clin Cancer Res. 2017 Jan 15;23(2):441-453. doi: 10.1158/1078-0432.CCR-16-0492. Epub 2016 Jul 19.

6.

Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation.

Rutkowski MR, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Brencicova E, Escovar-Fadul X, Nguyen JM, Cadungog MG, Zhang R, Salatino M, Tchou J, Rabinovich GA, Conejo-Garcia JR.

Cancer Cell. 2015 Jan 12;27(1):27-40. doi: 10.1016/j.ccell.2014.11.009. Epub 2014 Dec 18.

7.

Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.

Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA, Coukos G.

Cancer. 2009 Jul 1;115(13):2891-902. doi: 10.1002/cncr.24317.

8.

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.

Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB.

Mod Pathol. 2009 Mar;22(3):393-402. doi: 10.1038/modpathol.2008.191. Epub 2008 Dec 5.

9.

Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.

Zhang L, Huang J, Yang N, Liang S, Barchetti A, Giannakakis A, Cadungog MG, O'Brien-Jenkins A, Massobrio M, Roby KF, Katsaros D, Gimotty P, Butzow R, Weber BL, Coukos G.

Cancer Res. 2006 May 1;66(9):4627-35.

10.

Surgical resection of recurrent endometrial carcinoma.

Awtrey CS, Cadungog MG, Leitao MM, Alektiar KM, Aghajanian C, Hummer AJ, Barakat RR, Chi DS.

Gynecol Oncol. 2006 Sep;102(3):480-8. Epub 2006 Feb 21.

PMID:
16490236

Supplemental Content

Loading ...
Support Center